- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Patent holdings for IPC class A61P 33/02
Total number of patents in this class: 948
10-year publication summary
|
35
|
45
|
51
|
62
|
68
|
68
|
81
|
66
|
51
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11297 |
21 |
| CEVA Sante Animale | 689 |
16 |
| Anacor Pharmaceuticals, Inc. | 79 |
11 |
| Bayer Animal Health GmbH | 229 |
10 |
| Fundacao Oswaldo Cruz | 104 |
10 |
| Universidade Federal de Minas Gerais - Ufmg | 194 |
10 |
| Universidad de Granada | 298 |
9 |
| Centre National de La Recherche Scientifique | 10052 |
8 |
| Nihon Nohyaku Co., Ltd. | 315 |
8 |
| Vyera Pharmaceuticals, LLC | 9 |
8 |
| Kimberly-clark Worldwide, Inc. | 5519 |
7 |
| The Board of Trustees of the Leland Stanford Junior University | 6226 |
7 |
| President and Fellows of Harvard College | 5904 |
7 |
| Consejo Superior de Investigaciones Cientificas (csic) | 1316 |
7 |
| Institut de Recherche pour le Developpement (ird) | 154 |
7 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2827 |
7 |
| University of Dundee | 203 |
7 |
| Glaxosmithkline Intellectual Property Development Limited | 737 |
6 |
| Kao Corporation | 4898 |
6 |
| CJ Cheiljedang Corporation | 3240 |
6 |
| Other owners | 770 |